Amylyx Pharmaceuticals Inc. (AMLX): Guggenheim Starts Coverage With Buy and 215% Price Potential

Amylyx Pharmaceuticals Inc. (AMLX) has emerged as a company worth a closer look for investors following the recent repositioning of its development strategy. With a clear focus on developing therapies for diseases with high unmet medical needs, particularly in the rare disease space, the current pipeline presents exciting prospects and results. A key component of the Amylyx pipeline is Avexitid, a potential "First-in-Class" GLP-1 receptor antagonist. This molecule is currently being investigated in the pivotal Phase 3 LUCIDITY study for the treatment...